Insulin glargine and malignancy: an unwarranted alarm
No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis
Combined randomised controlled trial experience of malignancies in studies using insulin glargine
(c) 2005-2010 by Kinga Howorka, Jiri Pumprla. Research Group Functional Rehabilitation and Group Education eV., Center of Biomedical Engineering & Physics, Medical University Vienna, Austria